Verrica reported a net loss of $24.8 million in the third quarter of 2023, with a year-to-date net loss of $42.4 million. Despite this, the company made $2.8 million in product revenue from the sale of Ycanth to distributor FFF Enterprises Inc. The increase in expenses was attributed to commercial activities for Ycanth and compensation to expand the company’s sales force. Following FDA approval of Ycanth for the treatment of molluscum, Verrica continues to build momentum across its commercial operations and has seen broad awareness and interest in prescribing Ycanth across dermatology and pediatric practices.
Source link
Verrica reports net loss of $24.8 million in third quarter of 2023
